N/A
Completed N=61,737
Treximet ™ Pharmacy Budget Impact Model Database Validation Study
Migraine Disorders
Source: ClinicalTrials.gov NCT01332500 ↗
Enrolled (actual)
61,737
Serious AEs
—
Results posted
Apr 2011
Primary outcomePrimary: Mean Number of Triptan Tablets Per Participant in 6-month Follow-up Period: Treatment-naïve Analysis — 17.7; 18.4; 19.2; 21.5 tablets per participant — p=<0.001
Summary
The purpose of this retrospective claims database study was to compare the change in migraine-related prescription (i.e. NSAIDs, Opioids, Ergots) utilization among migraine suffers following initiation of Treximet ™ (sumatriptan/naproxen) compared with subjects initiating treatment with other orally available triptans. The study was used to validate the migraine-related prescription utilization patterns predicted by the Treximet ™ Budget Impact Model.
The SourceLx dataset from the family of Wolters Kluwer databases was used for this analysis. The database contains 30% of prescription claims filled in the United States (US), approximately 160 million patient lives. The data has broad representative coverage at both the geographic and payment levels.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Number of Triptan Tablets Per Participant in 6-month Follow-up Period: Treatment-naïve Analysis |
17.7; 18.4; 19.2; 21.5; 75.8; 80.1 | <0.001 sig |
| PRIMARY Mean Health Plan Cost Per Participant for Migraine-related Medications in 6-month Follow-up Period: Treatment-naïve Analysis |
284; 333; 9; 9; 38; 43 | <0.001 sig |
| PRIMARY Mean Total Cost (Health Plan Plus Participant Copay Costs) Per Participant for Migraine-related Medications in 6-month Follow-up Period: Treatment-naïve Analysis |
349; 397; 11; 12; 49; 54 | <0.001 sig |
| PRIMARY Mean Number of Triptan Tablets Per Participant in 6-month Follow-up Period: Treatment-switch Analysis |
24.4; 24.4; 20.9; 22.9; 88.4; 87.4 | 0.866 |
| PRIMARY Mean Health Plan Cost Per Participant for Migraine-related Medications in 6-month Follow-up Period: Treatment-switch Analysis |
375; 425; 8; 10; 47; 51 | <0.001 sig |
| PRIMARY Mean Total Cost (Health Plan Plus Participant Copay Costs) Per Participant for Migraine-related Medications in 6-month Follow-up Period: Treatment-switch Analysis |
462; 496; 12; 13; 61; 62 | <0.001 sig |
Eligibility Criteria
Inclusion Criteria
- At least one prescription claim for either Treximet ™ or orally administered triptan
- at least 18 years of age at index Rx date
- at least one prescription claim for any medication in the pre- and post-index period (proxy for continuous enrollment)
Exclusion Criteria
- Subjects receiving nasal sumatriptan at any time
- Subjects over 65 years of age
Data sourced from ClinicalTrials.gov (NCT01332500). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.